Continuous Infusion of Beta-Lactam Antibiotics in Severe Sepsis: A Multicenter Double-Blind, Randomized Controlled Trial
Publication in refereed journal

Times Cited
Web of Science213WOS source URL (as at 19/09/2020) Click here for the latest count
Altmetrics Information

Other information
AbstractBackground. Beta-lactam antibiotics are a commonly used treatment for severe sepsis, with intermittent bolus dosing standard therapy, despite a strong theoretical rationale for continuous administration. The aim of this trial was to determine the clinical and pharmacokinetic differences between continuous and intermittent dosing in patients with severe sepsis.
All Author(s) ListDulhunty JM, Roberts JA, Davis JS, Webb SAR, Bellomo R, Gomersall C, Shirwadkar C, Eastwood GM, Myburgh J, Paterson DL, Lipman J
Journal nameClinical Infectious Diseases
Volume Number56
Issue Number2
PublisherOxford University Press (OUP): Policy A1 - Oxford Open Option C
Pages236 - 244
LanguagesEnglish-United Kingdom
Keywordsclinical outcome; meropenem; pharmacokinetics; piperacillin-tazobactam; ticarcillin-clavulanate
Web of Science Subject CategoriesImmunology; IMMUNOLOGY; Infectious Diseases; INFECTIOUS DISEASES; Microbiology; MICROBIOLOGY

Last updated on 2020-20-09 at 01:31